Table 2: Benefits of subcutaneous and sublingual immunotherapy among participants with allergic asthma.

Author	Population	Included allergens	Comparison	Unadjusted standard mean difference (95% CI); I2; k		AMSTAR score*	Search date
				Symptom score	Medication score
Liao et al.,16 2015	Children with AA	House dust mite	SLIT v. placebo	-1.02(-2.07 to -0.33);92%; 8	-0.52(-1.75 to 0.71);85%; 3	7	February 2014
Normansell et al.,17 2015	AA ± AR	House dust mite, grass, pollen, birch pollen, cockroach, cat, Alternaria, Parietaria, Artemisia, olive pollen	SLIT v. placebo	-	-	11	March 2015
Lu et al.,18 2015	AA	House dust mite	SCIT v. placebo	-0.94(-1.58 to -0.29);92%; 13	-	7	February 2013
Tao et al.,19 2014	AA ± AR and/or conjunctivitis	House dust mite, grass, birch pollen	SLIT v. placebo	-0.74(-1.26 to -0.22);91%; NR	-0.78(-1.45 to -0.11);93%; NR	6	March 2012
Abramson et al.,1 2010	AA	House dust mite, pollen, dander, mould, latex	SCIT v. placebo	-0.59(-0.83 to -0.35);73%; 34	-	7	August 2005

Note: AA = allergic asthma, AR = allergic rhinitis, AMSTAR = Assessing the Methodological Quality of Systematic Reviews, k = number of included studies, NR = not reported, SCIT = subcutaneous immunotherapy, SLIT = sublingual immunotherapy.

*Maximum 11.